IL-23: Changing the verdict on IL-12 function in inflammation and autoimmunity

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1123-1136

  Kreymborg, Katharina ^a   Böhlmann, Ulrike ^a   Becher, Burkhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Autoimmune diseases; IL 12; IL 23; Inflammation; T cell

Indexed keywords

CD4 ANTIGEN; CYTOKINE; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P40; INTERLEUKIN 12P40 ANTIBODY; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 27; PROTEIN P35; RECEPTOR SUBUNIT; STAT PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; ARTHRITIS; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; COLLAGEN DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOREGULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN DOMAIN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH1 CELL;

ANIMALS; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION MEDIATORS; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS;

EID: 28844465015     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1123     Document Type: Review

References (117)

1. KOBAYASHI M, FITZ L, RYAN M et al.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. (1989) 170:827-845.
2. GATELY MK, DESAI BB, WOLITZKY AG et al.: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. (1991) 147:874-882.
3. GUBLER U, CHUA AO, SCHOENHAUT DS et al.: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA (1991) 88:4143-4147.
4. WOLF SF, TEMPLE PA, KOBAYASHI M et al.: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. (1991) 146:3074-3081.
5. MERBERG DM, WOLF SF, CLARK SC: Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol. Today (1992) 13:77-78.
6. GEARING DP, COSMAN D: Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell (1991) 66:9-10.
7. SCHOENHAUT DS, CHUA AO, WOLITZKY AG et al.: Cloning and expression of murine IL-12. J. Immunol. (1992) 148:3433-3440.
8. TRINCHIERI G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. (2003) 3:133-146.
9. BABIK JM, ADAMS E, TONE Y et al.: Expression of murine IL-12 is regulated by translational control of the p35 subunit. J. Immunol. (1999) 162:4069-4078.
10. MA X, TRINCHIERI G: Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol. (2001) 79:55-92.
11. MURPHY TL, CLEVELAND MG, KULESZA P, MAGRAM J, MURPHY KM: Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol. Cell Biol. (1995) 15:5258-5267.
12. MA X, CHOW JM, GRI G et al.: The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. (1996) 183:147-157.
13. MA X, NEURATH M, GRI G, TRINCHIERI G: Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter. J. Biol. Chem. (1997) 272:10389-10395.
14. PLEVY SE, GEMBERLING JH, HSU S, DORNER AJ, SMALE ST: Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell Biol. (1997) 17:4572-4588.
15. WANG IM, CONTURSI C, MASUMI A et al.: An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages. J. Immunol. (2000) 165:271-279.
16. TRINCHIERI G, WYSOCKA M, D'ANDREA A et al: Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog. Growth Factor Res. (1992) 4:355-368.
17. MEDZHITOV R: Toll-like receptors and innate immunity. Nat. Rev. Immunol. (2001) 1:135-145.
18. CELLA M, SCHEIDEGGER D, PALMER-LEHMANN K et al: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. (1996) 184:747-752.
19. BECHER B, BLAIN M, ANTEL JP, YOSHIDA TO: CD40 engagement stimulates IL-12 p70 production by human microglial cells: basis for Th1 polarization in the CNS. J. Neuroimmunol. (2000) 102:44-50.
20. FLESCH IE, HESS JH, HUANG S et al.: Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J. Exp. Med. (1995) 181:1615-1621.
21. BECHER B, DODELOT V, FEDOROWICZ V, ANTEL JP: Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. J. Clin. Invest. (1996) 98:1529-1543.
22. YOSHIDA A, KOIDE Y, UCHIJIMA M, YOSHIDA TO: IFN-gamma induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem. Biophys. Res. Commun. (1994) 198:857-861.
23. GRAN B, ZHANG GX, ROSTAMI A: Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit. Rev. Immunol. (2004) 24:111-128.
24. HSIEH CS, MACATONIA SE, TRIPP CS et al.: Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 260:547-549.
25. MANETTI R, PARRONCHI P, GIUDIZI MG et al.: Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper Type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. (1993) 177:1199-1204.
26. CHUA AO, CHIZZONITE R, DESAI BB et al.: Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J. Immunol. (1994) 153:128-136.
27. PRESKY DH, YANG H, MINETTI LJ et al.: A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA (1996) 93:14002-14007.
28. WATFORD WT, MORIGUCHI M, MORINOBU A, O'SHEA JJ: The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. (2003) 14:361-368.
29. DESAI BB, QUINN PM, WOLITZKY AG et al.: IL-12 receptor. II. Distribution and regulation of receptor expression. J. Immunol. (1992) 148:3125-3132.
30. PUCCETTI P, BELLADONNA ML, GROHMANN U: Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. Crit. Rev. Immunol. (2002) 22:373-390.
31. ROGGE L, PAPI A, PRESKY DH et al.: Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J. Immunol. (1999) 162:3926-3932.
32. ZOU J, PRESKY DH, WU CY, GUBLER U: Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases. J. Biol. Chem. (1997) 272:6073-6077.
33. BACON CM, PETRICOIN EF, 3rd, ORTALDO JR et al.: Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc. Natl. Acad. Sci. USA (1995) 92:7307-7311.
34. JACOBSON NG, SZABO SJ, WEBER-NORDT RM et al.: Interleukin 12 signaling in T helper Type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J. Exp. Med. (1995) 181:1755-1762.
35. COLOMBO MP, TRINCHIERI G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. (2002) 13:155-168.
36. NOVELLI F, CASANOVA JL: The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev. (2004) 15:367-377.
37. STEINMAN L: Multiple sclerosis: a two-stage disease. Nat. Immunol. (2001) 2:762-764.
38. TEUNISSEN CE, DIJKSTRA C, POLMAN C: Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. (2005) 4:32-41.
39. NICOLETTI F, PATTI F, COCUZZA C et al.: Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J. Neuroimmunol. (1996) 70:87-90.
40. DRULOVIC J, MOSTARICA-STOJKOVIC M, LEVIC Z et al.: Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J. Neurol. Sci. (1997) 147:145-150.
41. COMABELLA M, BALASHOV K, ISSAZADEH S et al.: Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. (1998) 102:671-678.
42. BOXEL-DEZAIRE AH, HOFF SC, VAN OOSTEN BW et al.: Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. (1999) 45:695-703.
43. FASSBENDER K, RAGOSCHKE A, ROSSOL S et al.: Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology (1998) 51:753-758.
44. OZENCI V, PASHENKOV M, KOUWENHOVEN M et al.: IL-12/ IL-12R system in multiple sclerosis. J. Neuroimmunol. (2001) 114:242-252.
45. BEN NUN A, WEKERLE H, COHEN IR: The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. (1981) 11:195-199.
46. PETTINELLI CB, MCFARLIN DE: Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1 + 2- T lymphocytes. J. Immunol. (1981) 127:1420-1423.
47. GRETER M, HEPPNER FL, LEMOS MP et al.: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. (2005) 11:328-334.
48. HEPPNER FL, GRETER M, MARINO D et al.: Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. (2005) 11:146-152.
49. DIAB A, ZHU J, XIAO BG, MUSTAFA M, LINK H: High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J. Neuropathol. Exp. Neurol. (1997) 56:641-650.
50. ISSAZADEH S, LORENTZEN JC, MUSTAFA MI et al.: Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. J. Neuroimmunol. (1996) 69:103-115.
51. ISSAZADEH S, MUSTAFA M, LJUNGDAHL A et al: Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J. Neurosci. Res. (1995) 40:579-590.
52. BRIGHT JJ, MUSURO BF, DU C, SRIRAM S: Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J. Neuroimmunol. (1998) 82:22-30.
53. SMITH T, HEWSON AK, KINGSLEY CI, LEONARD JP, CUZNER ML: Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am. J. Pathol. (1997) 150:1909-1917.
54. SEGAL BM, DWYER BK, SHEVACH EM: An interleukin (IL)-10/ IL-12 immunoregulatory, circuit controls susceptibility to autoimmune disease. J. Exp. Med. (1998) 187:537-546.
55. LEONARD JP, WALDBURGER KE, GOLDMAN SJ: Prevention of experimental autoinumme encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. (1995) 181:381-386.
56. MIOSSEC P: An update on the cytokine network in rheumatoid arthritis. Curr. Opin. Rheumatol. (2004) 16:218-222.
57. BRAND DD, KANG AH, ROSLONIEC EF: Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. (2003) 25:3-18.
58. GERMANN T, SZELIGA J, HESS H et al.: Administration of interleukin 12 in combination with Type II collagen induces severe arthritis in DBA/1 mice. Proc. Natl. Acad. Sci. USA (1995) 92:4823-4827.
59. MALFAIT AM, BUTLER DM, PRESKY DH et al.: Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. (1998) 111:377-383.
60. MCINTYRE KW, SHUSTER DJ, GILLOOLY KM et al: Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur. J. Immunol. (1996) 26:2933-2938.
61. MATTHYS P, VERMEIRE K, MITERA T et al.: Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur. J. Immunol. (1998) 28:2143-2151.
62. VERMEIRE K, HEREMANS H, VANDEPUTTE M et al.: Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. (1997) 158:5507-5513.
63. ADORINI L, GREGORI S, HARRISON LC: Understanding autoinumme diabetes: insights from mouse models. Trends Mol. Med. (2002) 8:31-38.
64. FALCONE M, SARVETNICK N: Cytokines that regulate autoimmune responses. Curr. Opin. Immunol. (1999) 11:670-676.
65. TREMBLEAU S, GERMANN T, GATELY MK, ADORINI L: The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today (1995) 16:383-386.
66. CHU CQ, WITTMER S, DALTON DK: Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med. (2000) 192:123-128.
67. FREI K, EUGSTER HP, BOPST M et al.: Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. (1997) 185:2177-2182.
68. WILLENBORG DO, FORDHAM S, BERNARD CC, COWDEN WB, RAMSHAW IA: IFN-gamma plays a Critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. (1996) 157:3223-3227.
69. MATTNER F, MAGRAM J, FERRANTE J et al.: Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. (1996) 26:1553-1559.
70. BECHER B, DURELL BG, NOELLE RJ: Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Inves.t (2002) 110:493-497.
71. GRAN B, ZHANG GX, YU S et al.: IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol. (2002) 169:7104-7110.
72. ZHANG GX, GRAN B, YU S et al.: Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J. Immunol. (2003) 170:2153-2160.
73. GILLESSEN S, CARVAJAL D, LING P et al.: Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. (1995) 25:200-206.
74. LING P, GATELY MK, GUBLER U et al.: Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J. Immunol. (1995) 154:116-127.
75. HA SJ, LEE CH, LEE SB et al.: A novel function of IL-12p40 as a chemotactic molecule for macrophages. J. Immunol. (1999) 163:2902-2908.
76. HUAUX F, ARRAS M, TOMASI D et al.: A profibrotic function of IL-12p40 in experimental pulmonary fibrosis. J. Immunol. (2002) 169:2653-2661.
77. LEHMANN J, BELLMANN S, WERNER C et al.: IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis. J. Immunol. (2001) 167:5304-5315.
78. LANKFORD CS, FRUCHT DM: A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. (2003) 73:49-56.
79. OPPMANN B, LESLEY R, BLOM B et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13:715-725.
80. FRUCHT DM: IL-23: a cytokine that acts on memory T cells. Sci. STKE. (2002) 2002:PE1.
81. VAN SEVENTER JM, NAGAI T, VAN SEVENTER GA: Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EB13 in activated human dendritic cells. J. Neuroimmunol. (2002) 133:60-71.
82. WESA A, GALY A. Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand. BMC. Immunol. (2002) 3:14.
83. RE F, STROMINGER JL: Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. (2001) 276:37692-37699.
84. PARHAM C, CHIRICA M, TIMANS J et al.: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. (2002) 168:5699-5708.
85. BELLADONNA ML, RENAULD JC, BIANCHI R et al: IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. (2002) 168:5448-5454.
86. CUA DJ, SHERLOCK J, CHEN Y et al: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 421:744-748.
87. WIEKOWSKI MT, LEACH MW, EVANS EW et al: Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. (2001) 166:7563-7570.
88. LANGRISH CL, CHEN Y, BLUMENSCHEIN WM et al: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. (2005) 201:233-240.
89. ZIOLKOWSKA M, KOC A, LUSZCZYKIEWICZ G et al: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. (2000) 164:2832-2838.
90. MURPHY CA, LANGRISH CL, CHEN Y et al: Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. (2003) 198:1951-1957.
91. HARRINGTON LE, HATTON RD, MANGAN PR et al: Interleukin 17-producing CD4(+) effector T cells develop via a lineage distinct from the T helper Type 1 and 2 lineages. Nat. Immunol. (2005) 6:1123-1132.
92. PARK H, LI Z, YANG XO et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. (2005) 6:1133-1141.
93. GHILARDI N, KLJAVIN N, CHEN Q et al.: Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J. Immunol. (2004) 172:2827-2833.
94. FERBER IA, BROCKE S, TAYLOR-EDWARDS C et al.: Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. (1996) 156:5-7.
95. AGGARWAL S, GHILARDI N, XIE MH, DE SAUVAGE FJ, GURNEY AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. (2003) 278:1910-1914.
96. HOLSCHER C, ATKINSON RA, ARENDSE B et al.: A protective and agonistic function of IL-12p40 in mycobacterial infection. J. Immunol. (2001) 167:6957-6966.
97. LI J, GRAN B, ZHANG GX et al: Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J. Neurol. Sci. (2003) 215:95-103.
98. SEKI N, SUDO Y, YOSHIOKA T et al: Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J. Immunol. (1988) 140:1477-1484.
99. STUART JM, DIXON FJ: Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. (1983) 158:378-392.
100. MAURI C, WILLIAMS RO, WALMSLEY M, FELDMANN M: Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. (1996) 26:1511-1518.
101. O'GARRA A, ARAI N: The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol. (2000) 10:542-550.
102. PFLANZ S, TIMANS JC, CHEUNG J et al: IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity (2002) 16:779-790.
103. SMITS HH, VAN BEELEN AJ, HESSLE C et al.: Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur, J. Immunol. (2004) 34:1371-1380.
104. PFLANZ S, HIBBERT L, MATTSON J et al.: WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. (2004) 172:2225-2231.
105. CHEN Q, GHILARDI N, WANG H et al.: Development of Th1-type immune responses requires the Type I cytokine receptor TCCR. Nature (2000) 407:916-920.
106. YOSHIDA H, HAMANO S, SENALDI G et al.: WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity (2001) 15:569-578.
107. VILLARINO AV, HUANG E, HUNTER CA: Understanding the pro- and anti-inflammatory properties of IL-27. J. Immunol. (2004) 173:715-720.
108. TAKEDA A, HAMANO S, YAMANAKA A et al: Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. (2003) 170:4886-4890.
109. LUCAS S, GHILARDI N, LI J, DE SAUVAGE FJ: IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA (2003) 100:15047-15052.
110. OWAKI T, ASAKAWA M, MORISHIMA N et al.: A role for IL-27 in early regulation of Th1 differentiation. J. Immunol. (2005) 175:2191-2200.
111. LI J, GRAN B, ZHANG GX, ROSTAMI A, KAMOUN M: IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J. Neurol. Sci. (2005) 232:3-9.
112. VANDENBROECK K, ALLOZA I, GADINA M, MATTHYS P: Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J. Pharm. Pharmacol. (2004) 56:145-160.
113. COSTA CL, SANDORA MR, NAKAJIMA A et al: Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J. Immunol. (2001) 167:2379-2387.
114. UYTTENHOVE C, ARENDSE B, STROOBANT V, BROMBACHER F, VAN SNICK J: Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. (2004) 34:3572-3581.
115. HOLSCHER C: Targeting IL-23 in autoimmunity. Curr. Opin. Investig. Drugs (2005) 6:489-495.
116. LANGRISH CL, MCKENZIE BS, WILSON NJ et al.: IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. (2004) 202:96-105.
117. LIEBERMAN LA, CARDILLO F, OWYANG AM et al.: IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. (2004) 173:1887-1893.